Bioequivalence evaluation of two oral formulations of quetiapine fumarate in healthy volunteers

Abstract

One bioequivalence study was carried out in healthy volunteers in order to compare the rate and extent of absorption of two oral formulations of quetiapine fumarate (CAS 111974-72-2) 25 mg film-coated tablet. Thirty subjects were administered quetiapine fumarate film-coated tablet of test and reference formulation in an open-label, randomised, fasting, two-period, two-sequence, crossover study. Blood samples were taken before and within 48 h after drug administration. Plasma concentrations were determined by LC/MS/MS. Log-transformed AUC and C_max values were tested for bioequivalence based on the ratios of the geometric means (test/reference). T_max was analysed nonparametrically. The 90% confidence intervals of the geometric mean values for the test/reference ratios for AUC_0–t and C_max were within the bioequivalence acceptance range of 80– 125%. It may be therefore concluded that the test formulation of quetiapine fumarate 25 mg film-coated tablet is bioequivalent to the reference product and can be prescribed interchangeably.

Key words

Atypical antipsychotic - Bioequivalence - Healthy volunteers - Pharmacokinetics - Quetiapine fumarate, tablet

• References

• 1 Seroquel® label information [Internet]. Food and Drug Administration; [cited 2010 Nov 15]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020639s045s046lbl.pdf
• 2 CPMP (Committee for Proprietary Medicinal Prodcuts) Guideline on the Investigation of Bioequivalence. London: 2010
• 3 Thyrum P, Wong YW, Yeh C. Single-dose pharmacokinetics of quetiapine in subjects with renal or hepatic impairment. Prog Neuro-Psychopharmacol Biol Psychiat. 2000; 24: 521-33
• 4 Good Clinical Practice Consolidated Guideline, International Conference on Harmonisation, E6. 1996.
• 5 Potkin SG, Thyrum PT, Alva G, Bera R, Yeh C, Arvantis LA. The safety and pharmacokinetics of quetiapine when coadministered with haloperidol, risperidone or thioridazine. J Clin Psychopharmacol. 2002; 22: 121-30
• 6 Chow SC, Liu JP. Power and sample size determination. In: Chow SC, Liu JP. editors Design and analysis of bioavailability and bioequivalence studies. 2nd ed. New York: Marcel Dekker; 2000: 125-160
• 7 Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987; 15: 657-80
• 8 Hauschke D, Steinijans VW, Diletti E. A distribution-free procedure for the statistical analysis of bioequivalence studies. Int J Clin Pharmacol Ther Toxicol. 1990; 28: 72-8
• 9 Wijnand HP. Updates of bioequivalence programs (including statistical power approximation by Student’s t). Corn-put Method Programs Biomed. 1994; 42: 275-81
• 10 Seroquel® Summary of Product Characteristics [Internet]. Spanish Medicines and Healthcare Products Agency; [cited 2010 Nov 17]. Available from: https://sinaem4.agemed.es/consaem/especialidad.do?metodo=verFichaWordPdf&codigo=63054&formato=pdf&formulario=FICHAS